Stock News•3 days ago
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
AbbVie's immunology franchise is being driven by Skyrizi and Rinvoq, with new indications, acquisitions, and partnerships building the next wave of growth.
MarketLens
AbbVie and Genmab's Epcoritamab: Why the Lymphoma Breakthrough is Still Undervalued
2 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•1 week ago
AbbVie's Etentamig Delivers 74% Response Rate in Pivotal Cancer Trial
AbbVie's etentamig achieved a 74% response rate in a pivotal cancer trial, boosting its pipeline prospects. Shares traded at $260.445 Thursday as investors weighed the drug's potential.
Stock News•1 months ago
Genmab: Multiple Late-Stage Readouts Ahead
Genmab shares have underperformed YTD despite strong Q2 royalty sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y). Up to five late-stage trial readouts for Epkinly, petosemtamab, and Rina-S are expected, s...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•2 hours ago
Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.
Stock News•2 hours ago
Viral AI Dommer Tweet: Engineered Panic?
Stock News•3 hours ago
Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.
Stock News•4 hours ago
Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.
Stock News•6 hours ago